The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

Journal of Clinical Investigation

Volumn 115, Issue 4, 2005, Pages 1068-1081

  Melillo, Rosa Marina ^a   Castellone, Maria Domenica ^a   Guarino, Valentina ^a   De Falco, Valentina ^a   Cirafici, Anna Maria ^a   Salvatore, Giuliana ^a   Caiazzo, Fiorina ^a   Basolo, Fulvio ^b   Giannini, Riccardo ^b   Kruhoffer, Mogens ^c   Orntoft, Torben ^c   Fusco, Alfredo ^a   Santoro, Massimo ^a,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Dipto Biol e Patol Cell e Molec   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CHEMOKINE; CXCL1 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PROTEIN RET; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MITOGENESIS; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID FOLLICLE CELL; THYROID PAPILLARY CARCINOMA; UPREGULATION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE; CELL PROLIFERATION; CHEMOKINES, CXC; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM INVASIVENESS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RATS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS;

EID: 20144387455     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200522758     Document Type: Article

References (51)

1. Rosai, J., Carcangiu, M.L., and DeLellis, R.A. 1992. Atlas of tumor pathology: tumors of the thyroid gland. 3rd series. Armed Forces Institute of Pathology. Washington, D.C., USA. 343 pp.
2. Manie, S., Santoro, M., Fusco, A., and Billaud, M. 2001. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet. 17:580-589.
3. Santoro, M., et al. 1992. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest. 89:1517-1522.
4. Fagin, J.A. 2002. Perspective: lessons learned from molecular genetic studies of thyroid cancer-insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology. 143:2025-2028.
5. Santoro, M., et al. 1996. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene. 12:1821-1826.
6. Buckwalter, T.L., et al. 2002. The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation. Oncogene. 21:8166-8172.
7. Fusco, A., et al. 2002. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am. J. Pathol. 160:2157-2167.
8. Pierotti, M.A. 2001. Chromosomal rearrangements in thyroid carcinomas: a recombination or death dilemma. Cancer Lett. 166:1-7.
9. Zhu, Z., Gandhi, M., Nikiforova, M.N., Fischer, A.H., and Nikiforov, Y.E. 2003. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am. J. Clin. Pathol. 120:71-77.
10. Kimura, E.T., et al. 2003. High prevalence of braf mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63:1454-1457.
11. Malumbres, M., and Barbacid, M. 2003. RAS oncogenes: the first 30 years. Nat. Rev. Cancer. 3:459-465.
12. Davies, H., et al. 2002. Mutations of the BRAF gene in human cancer. Nature. 417:949-954.
13. Cohen, Y., et al. 2003. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 95:625-627.
14. Soares, P., et al. 2003. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogens. 22:4578-4580.
15. Fagin, J.A. 2004. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol. 183:249-256.
16. Schlessinger, J., and Lemmon, M.A. 2003. SH2 and PTB domains in tyrosine kinase signaling [review]. Sci. STKE. 191:RE12.
17. Kawamoto, Y., et al. 2004. Identification of RET autophosphorylation sites by mass spectrometry. J. Biol. Chem. 279:14213-14224.
18. Pandey, A., et al. 1996. Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7. J. Biol. Chem. 271:10607-10610.
19. Borrello, M.G., et al. 1996. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol. Cell. Biol. 16:2151-2163.
20. Encinas, M., Crowder, R.J., Milbrandt, J., and Johnson, E.M., Jr. 2004. Tyrosine 981, a novel Ret autophosphorylation site, binds c-Src to mediate neuronal survival. J. Biol. Chem. 279:18262-18269.
21. Ichihara, M., Murakumo, Y., and Takahashi, M. 2004. RET and neuroendocrine tumors. Cancer Lett. 204:197-211.
22. Melillo, R.M., et al. 2001. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Mol. Cell. Biol. 21:4177-4187.
23. Castellone, M.D., et al. 2003. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene. 22:246-255.
24. Fusco, A., et al. 1987. One- and two-step transformations of tat thyroid epithelial cells by retroviral oncogenes. Mol. Cell. Biol. 9:3365-3370.
25. Santoro, M., et al. 1993. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ. 4:77-84.
26. Knauf, J.A., Kuroda, H., Basu, S., and Fagin, J.A. 2003. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene. 22:4406-4412.
27. Shirokawa, J.M., et al. 2000. Conditional apoptosis induced by oncogenic ras in thyroid cells. Mol. Endocrinol. 14:1725-1738.
28. Nikiforova, M.N., et al. 2003. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88:5399-5404.
29. Dhawan, P., and Richmond, A. 2002. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 72:9-18.
30. Luster, A.D. 1998. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:436-445.
31. Mellado, M., Rodriguez-Frade, J.M., Manes, S., and Martinez-A, C. 2001. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu. Rev. Immunol 19:397-421.
32. Scarpino, S., et al. 2000. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 156:831-837.
33. White, J.R., et al. 1998. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. 273:10095-10098.
34. Gao, P., et al. 2003. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J. Leukoc. Biol. 73:273-280.
35. Eblaghie, M.C., et al. 2003. Negative feedback regulation of FGF signaling levels by Pyst1/MKP3 in chick embryos. Curr. Biol. 13:1009-1018.
36. Carlomagno, F., et al. 2002. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62:7284-7290.
37. Lyons, J.F., Wilhelm, S., Hibner, B., and Bollag, G. 2001. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer. 8:219-225.
38. Liotta, L. A., and Kohn, B.C. 2001. The microenvironment of the tumour-host interface. Nature. 411:375-379.
39. Dahlman, T., et al. 2002. Collagen type I expression in experimental anaplastic thyroid carcinoma: regulation and relevance for tumorigenicity. Int. J. Cancer. 98:186-192.
40. Califano, D., et al. 1998. Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. Cancer Res. 58:823-828.
41. Huang, Y., et al. 2001. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl. Acad. Sci. U. S. A 98:15044-15049.
42. Bartolazzi, A., et al. 2001. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 357:1644-1650.
43. El-Rifai, W., et al. 2002. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 62:6823-6826.
44. Elsalini, O.A., von Gartzen, J., Cramer, M., and Rohr, K.B. 2003. Zebrafish hhex, nk2.1a, and pax2.1 regulate thyroid growth and differentiation downstream of Nodal-dependent transcription factors. Dev. Biol. 263:67-80.
45. Hackel, P.O., Gishizky, M., and Ullrich, A. 2001. Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol. Chem. 382:1649-1662.
46. Balkwill, F., and Mantovani, A. 2001. Inflammation and cancer: back to Virchow? Lancet. 357:539-545.
47. Coussens, L.M., and Werb, Z. 2002. Inflammation and cancer. Nature. 420:860-867.
48. Curcio, F., Ambesi-lmpiombato, F.S., Perrella, G., and Coon, H.G. 1994. Long-term culture and functional characterization of follicular cells from adult normal human thyroids. Proc. Natl. Acad. Sci. U. S. A. 91:9004-9008.
49. Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M., and Tuveson, D.A. 2003. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63:5198-5202.
50. Yuan, B., Latek, R., Hossbach, M., Tuschl, T., and Lewitter, F. 2004. siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids. Res. 32:W130-W134.
51. Castellone, M.D., et al. 2004. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene. 23:2188-2196.